昨天发了数据，股价寄了，d28暂时看不出疗效，cf还是难做....至于post hoc分析个d42的数，感觉也不太靠谱，这细胞都更新一遍了，而且 baseline variability略高；不过后面临床继续，1h26做个20人的：Initial analysis comparing FEV₁ values from Day 1 to Day 28 did not demonstrate meaningful improvement.
However, a post hoc exploratory analysis comparing the average of two pre-treatment FEV₁ measurements (screening and Day 1) for the baseline with the Day 42 post-treatment value, assuming an extended activity of functional CFTR protein triggered by daily ARCT-032 administration, suggests improvements in lung function, in four of six Class I CF participants with an average absolute increase of 3.8% and a relative increase of 5.1% in percent predicted FEV₁ (ppFEV₁).
While the magnitude of these changes falls within the range of natural variability of FEV1 measurements, such exploratory analyses can provide valuable directional signals, though they warrant cautionary interpretation.
$Arcturus医疗(ARCT)$ $福泰制药(VRTX)$